June 24, 2019
Regional Delivery of Mesothelin-Targeted CAR T-Cell Therapy Creates a Win for Solid Tumors BookmarkEmma Shtivelman, PhD
“In patients with malignant pleural disease, autologous mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy demonstrated clinical benefit with no significant toxicity, outcomes that may be due to the regional delivery of the CAR T cells to the intrapleural cavity rather than conventional systemic delivery. The phase I trial (ClinicalTrials.gov identifier: NCT02414269) results were presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting, held March 29–April 3 in Atlanta, Georgia (abstract CT036).”
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.